Paul Hastings Advised Viking Therapeutics on its $632.5 Million Public Offering of Common Stock

Paul Hastings LLP advised Viking Therapeutics, Inc. (Nasdaq: VKTX) in connection with the company’s underwritten offering of $632.5 million of shares of its common stock.  Morgan Stanley, Leerink Partners, William Blair, Raymond James, Stifel and Truist Securities acted as joint book-running managers for the offering, Oppenheimer & Co. acted as lead manager for the offering and BTIG, H.C. Wainwright & Co., Maxim Group LLC and Laidlaw & Company (U.K.) Ltd. acted as co-managers for the offering.

Viking is a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders. 

Chair of the Corporate Practice Jeff Hartlin and corporate partner Samantha Eldredge led the Paul Hastings team, which included associates Jenna Barba, Kelly Go, and Shawn Kim.

More details on the transaction can be found here.  

About Paul Hastings

With widely recognized elite teams in finance, mergers & acquisitions, private equity, restructuring and special situations, litigation, employment, and real estate, Paul Hastings is a premier law firm providing intellectual capital and superior execution globally to the world’s leading investment banks, asset managers, and corporations.